IceCure Medical (NASDAQ:ICCM) Releases Quarterly Earnings Results, Misses Estimates By $0.02 EPS

IceCure Medical (NASDAQ:ICCM) posted its quarterly earnings results on Tuesday. The company reported ($0.06) EPS for the quarter, missing the consensus estimate of ($0.04) by ($0.02), Zacks reports. IceCure Medical had a negative net margin of 445.61% and a negative return on equity of 248.23%. The company had revenue of $1.28 million for the quarter, compared to analysts’ expectations of $1.30 million.

Here are the key takeaways from IceCure Medical’s conference call:

• FDA clearance plus the American Society of Breast Surgeons’ new guideline recommending cryoablation are cited as major adoption catalysts and the company notes ProSense is the first and only FDA‑cleared device for breast cancer treatment.
• Management reported record unit sales and a record Q4 (~$1.3M) driving full‑year 2025 revenue of $3.4M, with a growing pipeline converting to signed contracts and installations at prominent hospital systems.
• Current reimbursement is under a CPT Category III code (~$4,000 facility payment) and IceCure has applied for transitional pass‑through (up to ~$900) and plans a CPT‑1 submission for physician payment, which management views as an inflection point if approved.
• The FDA requires a 30‑site post‑marketing study (majority of sites identified but not all agreements signed), with onboarding expected in 3–6 months and patient enrollment slated to begin late summer, potentially affecting rollout timing.
• International expansion efforts include a Health Canada Class III amendment for patients 60+ (decision expected H2 2026) and progress toward a Japanese submission with partner Terumo, which management says is already boosting global demand.

IceCure Medical Stock Performance

Shares of ICCM stock opened at $0.60 on Thursday. The stock’s 50 day simple moving average is $0.63 and its 200 day simple moving average is $0.75. IceCure Medical has a twelve month low of $0.54 and a twelve month high of $1.50. The company has a market capitalization of $41.23 million, a price-to-earnings ratio of -2.50 and a beta of 0.29.

Hedge Funds Weigh In On IceCure Medical

An institutional investor recently bought a new position in IceCure Medical stock. Jane Street Group LLC bought a new position in shares of IceCure Medical Ltd. (NASDAQ:ICCM) during the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 109,638 shares of the company’s stock, valued at approximately $67,000. Jane Street Group LLC owned approximately 0.16% of IceCure Medical as of its most recent SEC filing. Institutional investors and hedge funds own 0.62% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts recently issued reports on the company. Wall Street Zen raised IceCure Medical from a “sell” rating to a “hold” rating in a research report on Saturday, February 7th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of IceCure Medical in a research report on Thursday, January 22nd. One research analyst has rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average price target of $2.64.

IceCure Medical Company Profile

IceCure Medical Ltd. (NASDAQ: ICCM) is a clinical-stage medical device company specializing in the development and commercialization of proprietary cryoablation systems for the treatment of tumors and other pathological tissues. The company’s core technology employs a unique liquid-nitrogen-based platform to deliver rapid cooling through fine-gauge cryoprobes, enabling precise and minimally invasive tissue ablation under imaging guidance. IceCure’s lead product, ProSense, is designed to offer a single-probe approach that can be deployed in an outpatient setting, reducing procedure time and patient recovery periods.

Originally founded in Israel, IceCure Medical obtained its first CE mark for the treatment of benign breast tumors and fibroadenomas in 2017.